NEW YORK – Despite a shortfall in second-quarter revenues due to delayed population genomics projects and weakness in the direct-to-consumer genetic testing market, Illumina believes that growth in these areas will eventually return, according to CEO and President Francis deSouza.

During a conference call to discuss Illumina's second quarter results this week, he provided additional details on why Q2 revenues stayed below expectations and highlighted other areas of potential growth, including oncology, clinical genetics, reproductive health, and clinical research.